<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Loeys-Dietz Syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "â†³ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Loeys-Dietz Syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Loeys-Dietz Syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0018954" target="_blank">
                        MONDO:0018954
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Connective Tissue Disorders</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Marfan and Marfan-related Disorders</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder caused by heterozygous mutations in genes encoding components of the TGF-beta signaling pathway, most commonly TGFBR1 and TGFBR2. It is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Additional features include craniosynostosis, skeletal abnormalities (scoliosis, pectus deformity, joint laxity or contractures), thin translucent skin, and immunologic features (food allergy, eosinophilic gastrointestinal disease). LDS carries a high risk of aortic dissection at smaller aortic diameters than Marfan syndrome, with a mean age at death of 26.0 years in initial cohorts. Early diagnosis and aggressive surgical management are critical.

            </p>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2026-02-13T00:31:42Z">2026-02-13</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-02-13T01:20:31Z">2026-02-13</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <a class="stat-link" href="#inheritance">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Inheritance</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">15</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        
        <div class="card" id="inheritance">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #92400e;">ðŸ‘ª</div>
                <h2 class="card-title">Inheritance</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box inheritance-box">
                <div class="item-name">
                    Autosomal Dominant
                    
                </div>
                
                <div class="item-desc">Autosomal dominant inheritance with variable expressivity.
</div>
                
                
    
    
    
    
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"LDS, an autosomal-dominant connective tissue disorder first characterized by aortic aneurysms and generalized arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. confirm autosomal dominant inheritance in this comprehensive clinical management review.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">â—†</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">5</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Loeys-Dietz Syndrome Type 1
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by mutations in TGFBR1. Often presents with more severe craniofacial features including craniosynostosis. Earlier cardiovascular surgery (mean age 16.9 years) and death (22.6 years) compared to type 2.
</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Loeys-Dietz Syndrome Type 2
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by mutations in TGFBR2. More prominent cutaneous features and phenotypic overlap with vascular Ehlers-Danlos syndrome. Later surgery (mean age 26.9 years) and death (31.8 years) than type 1.
</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Loeys-Dietz Syndrome Type 3
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by mutations in SMAD3. Associated with early-onset osteoarthritis (aneurysms-osteoarthritis syndrome) and increased prevalence of mitral valve prolapse.
</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Loeys-Dietz Syndrome Type 4
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by mutations in TGFB2. Generally milder vascular phenotype with lower prevalence of musculoskeletal involvement.
</div>
                    
                    
                    
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Loeys-Dietz Syndrome Type 5
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Caused by mutations in TGFB3. Milder phenotype with variable penetrance.
</div>
                    
                    
                    
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">âš™</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Paradoxical TGF-beta Signaling</div>
                
                <div class="item-desc">Loss-of-function mutations in TGF-beta receptors paradoxically lead to increased TGF-beta signaling in the aortic wall, mediated through non-canonical pathways and compensatory upregulation. This results in excessive SMAD2/3 phosphorylation and activation of ERK and p38 MAPK downstream targets that promote extracellular matrix degradation.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Vascular Smooth Muscle Cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000359" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000057" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        TGF-beta Signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007179" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        SMAD Signaling
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0060395" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21493862" target="_blank">PMID:21493862</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2 are activated in a mouse model of MFS, and both are inhibited by therapies directed against TGFbeta"</div>
                
                
                <div class="evidence-explanation">Holm et al. demonstrate that both canonical (Smad2) and noncanonical (ERK1/2) TGF-beta signaling are activated in aortic disease, and selective ERK1/2 inhibition ameliorates aortic growth while Smad4 deficiency exacerbates disease.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate and is caused by heterozygous mutations in the genes encoding transforming growth factor beta receptors 1 and 2 (TGFBR1 and TGFBR2, respectively)"</div>
                
                
                <div class="evidence-explanation">The landmark Loeys et al. 2006 NEJM paper establishes TGF-beta receptor mutations as the cause and defines the clinical triad.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Noncanonical MAPK Pathway Activation</div>
                
                <div class="item-desc">In addition to canonical SMAD signaling, noncanonical ERK1/2 and JNK pathways are prominently activated in LDS aortic tissue. Selective inhibition of ERK1/2 ameliorates aortic growth, while JNK antagonism is also protective. These non-SMAD pathways may be the primary drivers of aortic disease progression.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        ERK Cascade
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0070371" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        JNK Cascade
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007254" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21493862" target="_blank">PMID:21493862</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"noncanonical (Smad-independent) TGFbeta signaling is a prominent driver of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1 pathways is a potential therapeutic strategy for the disease"</div>
                
                
                <div class="evidence-explanation">Holm et al. establish noncanonical TGF-beta signaling via ERK and JNK as key drivers of aortic aneurysm progression.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Extracellular Matrix Degradation</div>
                
                <div class="item-desc">Enhanced TGF-beta signaling leads to upregulation of matrix metalloproteinases (MMPs) and reduced expression of tissue inhibitors, causing degradation of elastic fibers and collagen in the arterial wall. This weakens the vessel wall leading to aneurysm formation and dissection.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Extracellular Matrix Disassembly
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0022617" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Elastic Fiber Assembly
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0048251" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        Aorta
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000947" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Skeletal Development Disruption</div>
                
                <div class="item-desc">TGF-beta signaling is critical for skeletal development, particularly in suture closure and vertebral column formation. Dysregulated signaling leads to craniosynostosis, scoliosis, and cervical spine instability. Cervical spine findings are prominent in LDS 1/2 (51% of patients).
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Skeletal System Development
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001501" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Cranial Suture Morphogenesis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0060365" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cervical spine findings are prominent features in LDS 1/2 (51%), but presence in LDS 3 and 4 is unknown"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. document cervical spine abnormalities in over half of LDS type 1/2 patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Immune Dysregulation</div>
                
                <div class="item-desc">LDS is associated with a high prevalence of immunologic features including food allergy (31%), eosinophilic gastrointestinal disease, asthma, eczema, and allergic rhinitis. TGF-beta pathway disruption affects immune regulation and mucosal tolerance.
</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Immune Response Regulation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0050776" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"LDS has been associated with a high prevalence of immunologic features including asthma, food allergy, eczema, and allergic rhinitis"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. document significant immune dysregulation in LDS, with food allergy prevalence of 31% compared to 6-8% in the general population.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">â—</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">15</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Eye<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Head and Neck<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Immune<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Integument<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Limbs<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Musculoskeletal<span class="pill-count">(6)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-8">Prenatal and Birth<span class="pill-count">(1)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Aortic Root Aneurysm
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002616" target="_blank">
                                Aortic root aneurysm
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002616)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The natural history of both types was characterized by aggressive arterial aneurysms (mean age at death, 26.0 years) and a high incidence of pregnancy-related complications (in 6 of 12 women)"</div>
                
                
                <div class="evidence-explanation">Loeys et al. document aggressive aneurysmal disease with early mortality in 52 families with LDS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"dissections have occurred in individuals with LDS 1, 2, or 3 at aortic dimensions of 3.9-4.0 cm"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. note dissections at smaller diameters than Marfan syndrome, supporting more aggressive surgical thresholds.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arterial Tortuosity
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0005116" target="_blank">
                                Arterial tortuosity
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0005116)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35662564" target="_blank">PMID:35662564</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the most commonly reported features and complications being: aortic aneurysms and dissections, arterial tortuosity, high arched palate, abnormal uvula and hypertelorism"</div>
                
                
                <div class="evidence-explanation">Systematic review of 3896 LDS cases confirms arterial tortuosity as one of the most common features.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypertelorism
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000316" target="_blank">
                                Hypertelorism
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000316)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate"</div>
                
                
                <div class="evidence-explanation">Hypertelorism is part of the defining diagnostic triad.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Head and Neck
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Bifid Uvula
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000193" target="_blank">
                                Bifid uvula
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000193)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The disease is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate"</div>
                
                
                <div class="evidence-explanation">Bifid uvula is part of the defining diagnostic triad.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Craniosynostosis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001363" target="_blank">
                                Craniosynostosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001363)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Most commonly, the sagittal suture is prematurely closed, but the coronal, metopic, and squamosal sutures can also be involved"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. describe the pattern of suture involvement in LDS craniosynostosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Immune
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Food Allergy
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0500093" target="_blank">
                                Food allergy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0500093)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A conservative prevalence estimate of food allergies in this population is 31% (compared with 6-8% prevalence in the general population)"</div>
                
                
                <div class="evidence-explanation">Food allergy prevalence is approximately 4-5 times higher in LDS than in the general population.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Translucent Skin
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0010648" target="_blank">
                                Dermal translucency
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0010648)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cutaneous findings in LDS include velvety, thin, translucent skin with easy bruising and visible veins"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. describe the cutaneous features of LDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Limbs
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Clubfoot
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001762" target="_blank">
                                Talipes equinovarus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001762)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">6</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Scoliosis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002650" target="_blank">
                                Scoliosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002650)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pectus Excavatum
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000767" target="_blank">
                                Pectus excavatum
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000767)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Skeletal features in all types of LDS can show overlap with Marfan syndrome, including pectus deformity, scoliosis, and flat feet"</div>
                
                
                <div class="evidence-explanation">Pectus deformity confirmed across all LDS types in clinical review.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Joint Hypermobility
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001382" target="_blank">
                                Joint hypermobility
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001382)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Extremity contractures in conjunction with joint hyperextension are unusual in the general population but common in LDS"</div>
                
                
                <div class="evidence-explanation">The coexistence of contractures and hypermobility is a distinctive feature of LDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cervical Spine Instability
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0010646" target="_blank">
                                Cervical spine instability
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0010646)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cervical spine findings are prominent features in LDS 1/2 (51%)"</div>
                
                
                <div class="evidence-explanation">Over half of LDS type 1/2 patients have cervical spine abnormalities.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Osteoporosis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000939" target="_blank">
                                Osteoporosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000939)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"at least 60% of patients had low or very low bone mineral density in the spine, hip, and/or femoral neck"</div>
                
                
                <div class="evidence-explanation">High fracture risk and low BMD documented in LDS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Early-Onset Osteoarthritis
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002758" target="_blank">
                                Osteoarthritis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002758)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21217753" target="_blank">PMID:21217753</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis"</div>
                
                
                <div class="evidence-explanation">van de Laar et al. identified SMAD3 mutations as cause of aneurysms-osteoarthritis syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35662564" target="_blank">PMID:35662564</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"LDS Type 3 demonstrated an increased prevalence of mitral valve prolapse and arthritis"</div>
                
                
                <div class="evidence-explanation">Systematic review confirms LDS type 3 association with arthritis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-8">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Prenatal and Birth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Pregnancy-Related Vascular Complications
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001197" target="_blank">
                                Abnormality of prenatal development or birth
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001197)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"a high incidence of pregnancy-related complications (in 6 of 12 women)"</div>
                
                
                <div class="evidence-explanation">50% pregnancy complication rate in initial LDS cohort.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35662564" target="_blank">PMID:35662564</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Amongst 222 women who underwent 522 pregnancies, 4% experienced an aortic dissection and the peripartum mortality rate was 1%"</div>
                
                
                <div class="evidence-explanation">Large systematic review quantifies pregnancy risks in LDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">ðŸ§¬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TGFBR1 Mutations (LDS Type 1)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We found a mutation in TGFBR1 or TGFBR2 in all probands with typical Loeys-Dietz syndrome (type I) and in 12 probands presenting with vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)"</div>
                
                
                <div class="evidence-explanation">100% of typical LDS probands had TGFBR1 or TGFBR2 mutations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TGFBR2 Mutations (LDS Type 2)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in either TGFBR1 or TGFBR2 predispose patients to aggressive and widespread vascular disease"</div>
                
                
                <div class="evidence-explanation">Loeys et al. establish TGFBR2 mutations as causative for LDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SMAD3 Mutations (LDS Type 3)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21217753" target="_blank">PMID:21217753</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the disease is caused by mutations in SMAD3. This gene encodes a member of the TGF-beta pathway that is essential for TGF-beta signal transmission"</div>
                
                
                <div class="evidence-explanation">van de Laar et al. identified SMAD3 as the causal gene for the aneurysms-osteoarthritis syndrome (LDS type 3).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TGFB2 Mutations (LDS Type 4)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Chromosome deletions encompassing the TGFB2 gene (and hypothetically the SMAD3 gene) causing haploinsufficiency are sufficient to cause features of LDS"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. describe TGFB2 haploinsufficiency as sufficient for LDS features.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TGFB3 Mutations (LDS Type 5)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">ðŸ’Š</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Prophylactic Aortic Root Replacement
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Valve-sparing aortic root replacement at lower thresholds than Marfan syndrome. For adults with LDS 1/2, surgical repair is recommended at 4.0 cm maximal aortic root dimension. For children, aggressive medication may delay surgery until aortic annulus reaches 2.0-2.2 cm.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"For adults with LDS 1 or 2, this includes surgical repair of the aortic root once the maximal dimension of the aortic root reaches 4.0 cm"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. recommend surgical threshold of 4.0 cm for adult LDS patients, lower than the 5.0 cm for Marfan syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16928994" target="_blank">PMID:16928994</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"There were 59 vascular surgeries in the cohort, with one death during the procedure. This low rate of intraoperative mortality distinguishes the Loeys-Dietz syndrome from vascular Ehlers-Danlos syndrome"</div>
                
                
                <div class="evidence-explanation">Low surgical mortality supports aggressive prophylactic surgery approach in LDS, unlike vascular EDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Losartan/ARB Therapy
                    
                </div>
                
                <div class="item-desc">Angiotensin receptor blockers (particularly losartan) are used to reduce TGF-beta signaling. Losartan was shown to prevent aortic aneurysm in a mouse model by antagonizing TGF-beta through AT1 receptor blockade. Optimal dosing: 2.0 mg/kg/day for children, 100 mg/day for adults.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16601194" target="_blank">PMID:16601194</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan"</div>
                
                
                <div class="evidence-explanation">Habashi et al. provide the mechanistic rationale for losartan therapy in TGF-beta pathway disorders.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Angiotensin receptor blockers may be particularly beneficial due to their effects on the TGF-beta signaling cascade"</div>
                
                
                <div class="evidence-explanation">Clinical guidelines support ARB use for their pathway-specific effects beyond blood pressure reduction.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Beta-Blocker Therapy
                    
                </div>
                
                <div class="item-desc">Beta-blockers to reduce hemodynamic stress on the aorta. Standard-of-care for syndromic aneurysm conditions, often used in combination with ARBs.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Beta-Blockade to reduce hemodynamic stress on the vasculature has been the standard-of-care treatment for individuals with syndromic aneurysm conditions"</div>
                
                
                <div class="evidence-explanation">Beta-blockers are established standard of care for LDS vascular management.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Comprehensive Vascular Surveillance
                    
                </div>
                
                <div class="item-desc">Regular MRA or CTA imaging of the entire arterial tree from head to pelvis, as aneurysms can occur throughout the vascular system. Full vascular imaging at initial evaluation and at 2-year intervals if no aneurysms identified.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24577266" target="_blank">PMID:24577266</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Diagnostic or baseline vascular imaging through magnetic resonance angiography or computerized tomography angiography with three-dimensional reconstruction of the head, neck, chest, abdomen, and pelvis should be performed"</div>
                
                
                <div class="evidence-explanation">MacCarrick et al. recommend comprehensive head-to-pelvis imaging for all LDS patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Loeys-Dietz Syndrome
creation_date: &#39;2026-02-13T00:31:42Z&#39;
updated_date: &#39;2026-02-13T01:20:31Z&#39;
category: Mendelian
description: &gt;
  Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder
  caused by heterozygous mutations in genes encoding components of the TGF-beta
  signaling pathway, most commonly TGFBR1 and TGFBR2. It is characterized by the
  triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or
  cleft palate. Additional features include craniosynostosis, skeletal abnormalities
  (scoliosis, pectus deformity, joint laxity or contractures), thin translucent skin,
  and immunologic features (food allergy, eosinophilic gastrointestinal disease).
  LDS carries a high risk of aortic dissection at smaller aortic diameters than
  Marfan syndrome, with a mean age at death of 26.0 years in initial cohorts.
  Early diagnosis and aggressive surgical management are critical.
disease_term:
  preferred_term: Loeys-Dietz syndrome
  term:
    id: MONDO:0018954
    label: Loeys-Dietz syndrome
parents:
- Connective Tissue Disorders
- Marfan and Marfan-related Disorders
has_subtypes:
- name: Loeys-Dietz Syndrome Type 1
  description: &gt;
    Caused by mutations in TGFBR1. Often presents with more severe
    craniofacial features including craniosynostosis. Earlier cardiovascular
    surgery (mean age 16.9 years) and death (22.6 years) compared to type 2.
- name: Loeys-Dietz Syndrome Type 2
  description: &gt;
    Caused by mutations in TGFBR2. More prominent cutaneous features
    and phenotypic overlap with vascular Ehlers-Danlos syndrome.
    Later surgery (mean age 26.9 years) and death (31.8 years) than type 1.
- name: Loeys-Dietz Syndrome Type 3
  description: &gt;
    Caused by mutations in SMAD3. Associated with early-onset osteoarthritis
    (aneurysms-osteoarthritis syndrome) and increased prevalence of mitral
    valve prolapse.
- name: Loeys-Dietz Syndrome Type 4
  description: &gt;
    Caused by mutations in TGFB2. Generally milder vascular phenotype
    with lower prevalence of musculoskeletal involvement.
- name: Loeys-Dietz Syndrome Type 5
  description: &gt;
    Caused by mutations in TGFB3. Milder phenotype with variable penetrance.
inheritance:
- name: Autosomal Dominant
  description: &gt;
    Autosomal dominant inheritance with variable expressivity.
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    snippet: &gt;-
      LDS, an autosomal-dominant connective tissue disorder first
      characterized by aortic aneurysms and generalized arterial tortuosity,
      hypertelorism, and bifid/broad uvula or cleft palate
    explanation: &gt;-
      MacCarrick et al. confirm autosomal dominant inheritance in this
      comprehensive clinical management review.
pathophysiology:
- name: Paradoxical TGF-beta Signaling
  description: &gt;
    Loss-of-function mutations in TGF-beta receptors paradoxically lead to
    increased TGF-beta signaling in the aortic wall, mediated through
    non-canonical pathways and compensatory upregulation. This results in
    excessive SMAD2/3 phosphorylation and activation of ERK and p38 MAPK
    downstream targets that promote extracellular matrix degradation.
  cell_types:
  - preferred_term: Vascular Smooth Muscle Cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  - preferred_term: Fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: TGF-beta Signaling
    term:
      id: GO:0007179
      label: transforming growth factor beta receptor signaling pathway
  - preferred_term: SMAD Signaling
    term:
      id: GO:0060395
      label: SMAD protein signal transduction
  evidence:
  - reference: PMID:21493862
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &gt;-
      extracellular signal-regulated kinase (ERK) 1 and 2 and Smad2
      are activated in a mouse model of MFS, and both are inhibited by
      therapies directed against TGFbeta
    explanation: &gt;-
      Holm et al. demonstrate that both canonical (Smad2) and noncanonical
      (ERK1/2) TGF-beta signaling are activated in aortic disease, and
      selective ERK1/2 inhibition ameliorates aortic growth while Smad4
      deficiency exacerbates disease.
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      The disease is characterized by the triad of arterial tortuosity and
      aneurysms, hypertelorism, and bifid uvula or cleft palate and is
      caused by heterozygous mutations in the genes encoding transforming
      growth factor beta receptors 1 and 2 (TGFBR1 and TGFBR2, respectively)
    explanation: &gt;-
      The landmark Loeys et al. 2006 NEJM paper establishes TGF-beta receptor
      mutations as the cause and defines the clinical triad.
- name: Noncanonical MAPK Pathway Activation
  description: &gt;
    In addition to canonical SMAD signaling, noncanonical ERK1/2 and JNK
    pathways are prominently activated in LDS aortic tissue. Selective
    inhibition of ERK1/2 ameliorates aortic growth, while JNK antagonism
    is also protective. These non-SMAD pathways may be the primary
    drivers of aortic disease progression.
  biological_processes:
  - preferred_term: ERK Cascade
    term:
      id: GO:0070371
      label: ERK1 and ERK2 cascade
  - preferred_term: JNK Cascade
    term:
      id: GO:0007254
      label: JNK cascade
  evidence:
  - reference: PMID:21493862
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &gt;-
      noncanonical (Smad-independent) TGFbeta signaling is a prominent driver
      of aortic disease in MFS mice, and inhibition of the ERK1/2 or JNK1
      pathways is a potential therapeutic strategy for the disease
    explanation: &gt;-
      Holm et al. establish noncanonical TGF-beta signaling via ERK and JNK
      as key drivers of aortic aneurysm progression.
- name: Extracellular Matrix Degradation
  description: &gt;
    Enhanced TGF-beta signaling leads to upregulation of matrix
    metalloproteinases (MMPs) and reduced expression of tissue inhibitors,
    causing degradation of elastic fibers and collagen in the arterial wall.
    This weakens the vessel wall leading to aneurysm formation and dissection.
  biological_processes:
  - preferred_term: Extracellular Matrix Disassembly
    term:
      id: GO:0022617
      label: extracellular matrix disassembly
  - preferred_term: Elastic Fiber Assembly
    term:
      id: GO:0048251
      label: elastic fiber assembly
  locations:
  - preferred_term: Aorta
    term:
      id: UBERON:0000947
      label: aorta
- name: Skeletal Development Disruption
  description: &gt;
    TGF-beta signaling is critical for skeletal development, particularly
    in suture closure and vertebral column formation. Dysregulated signaling
    leads to craniosynostosis, scoliosis, and cervical spine instability.
    Cervical spine findings are prominent in LDS 1/2 (51% of patients).
  biological_processes:
  - preferred_term: Skeletal System Development
    term:
      id: GO:0001501
      label: skeletal system development
  - preferred_term: Cranial Suture Morphogenesis
    term:
      id: GO:0060365
      label: cranial suture morphogenesis
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Cervical spine findings are prominent features in LDS 1/2 (51%),
      but presence in LDS 3 and 4 is unknown
    explanation: &gt;-
      MacCarrick et al. document cervical spine abnormalities in over
      half of LDS type 1/2 patients.
- name: Immune Dysregulation
  description: &gt;
    LDS is associated with a high prevalence of immunologic features
    including food allergy (31%), eosinophilic gastrointestinal disease,
    asthma, eczema, and allergic rhinitis. TGF-beta pathway disruption
    affects immune regulation and mucosal tolerance.
  biological_processes:
  - preferred_term: Immune Response Regulation
    term:
      id: GO:0050776
      label: regulation of immune response
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      LDS has been associated with a high prevalence of immunologic features
      including asthma, food allergy, eczema, and allergic rhinitis
    explanation: &gt;-
      MacCarrick et al. document significant immune dysregulation in LDS,
      with food allergy prevalence of 31% compared to 6-8% in the
      general population.
phenotypes:
- name: Aortic Root Aneurysm
  description: &gt;
    Progressive dilation of the aortic root, occurring at earlier ages and
    smaller diameters than in Marfan syndrome. Dissections have occurred
    at aortic dimensions of 3.9-4.0 cm, unlike the 5.0 cm threshold
    in Marfan syndrome.
  phenotype_term:
    preferred_term: Aortic root aneurysm
    term:
      id: HP:0002616
      label: Aortic root aneurysm
  evidence:
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      The natural history of both types was characterized by aggressive
      arterial aneurysms (mean age at death, 26.0 years) and a high
      incidence of pregnancy-related complications (in 6 of 12 women)
    explanation: &gt;-
      Loeys et al. document aggressive aneurysmal disease with early mortality
      in 52 families with LDS.
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      dissections have occurred in individuals with LDS 1, 2, or 3 at
      aortic dimensions of 3.9-4.0 cm
    explanation: &gt;-
      MacCarrick et al. note dissections at smaller diameters than Marfan
      syndrome, supporting more aggressive surgical thresholds.
- name: Arterial Tortuosity
  description: &gt;
    Widespread arterial tortuosity, particularly of the head and neck
    vessels. A distinguishing feature from Marfan syndrome. Increased
    vertebral arterial tortuosity is a marker of adverse aortic outcome.
  phenotype_term:
    preferred_term: Arterial tortuosity
    term:
      id: HP:0005116
      label: Arterial tortuosity
  evidence:
  - reference: PMID:35662564
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      the most commonly reported features and complications being: aortic
      aneurysms and dissections, arterial tortuosity, high arched palate,
      abnormal uvula and hypertelorism
    explanation: &gt;-
      Systematic review of 3896 LDS cases confirms arterial tortuosity
      as one of the most common features.
- name: Hypertelorism
  description: &gt;
    Wide-spaced eyes, part of the characteristic craniofacial gestalt
    and the diagnostic triad.
  phenotype_term:
    preferred_term: Hypertelorism
    term:
      id: HP:0000316
      label: Hypertelorism
  evidence:
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      The disease is characterized by the triad of arterial tortuosity and
      aneurysms, hypertelorism, and bifid uvula or cleft palate
    explanation: &gt;-
      Hypertelorism is part of the defining diagnostic triad.
- name: Bifid Uvula
  description: &gt;
    Bifid or broad uvula, a hallmark feature often used for clinical
    screening. May range from broad uvula to overt cleft palate.
  phenotype_term:
    preferred_term: Bifid uvula
    term:
      id: HP:0000193
      label: Bifid uvula
  evidence:
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      The disease is characterized by the triad of arterial tortuosity and
      aneurysms, hypertelorism, and bifid uvula or cleft palate
    explanation: &gt;-
      Bifid uvula is part of the defining diagnostic triad.
- name: Craniosynostosis
  description: &gt;
    Premature fusion of cranial sutures, most commonly the sagittal suture
    but also coronal, metopic, and squamosal. More common in LDS type 1.
  phenotype_term:
    preferred_term: Craniosynostosis
    term:
      id: HP:0001363
      label: Craniosynostosis
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Most commonly, the sagittal suture is prematurely closed, but the
      coronal, metopic, and squamosal sutures can also be involved
    explanation: &gt;-
      MacCarrick et al. describe the pattern of suture involvement in LDS
      craniosynostosis.
- name: Scoliosis
  description: &gt;
    Progressive scoliosis requiring monitoring and potential surgical
    intervention.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
- name: Pectus Excavatum
  description: &gt;
    Pectus excavatum or pectus carinatum, similar to Marfan syndrome.
  phenotype_term:
    preferred_term: Pectus excavatum
    term:
      id: HP:0000767
      label: Pectus excavatum
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Skeletal features in all types of LDS can show overlap with Marfan
      syndrome, including pectus deformity, scoliosis, and flat feet
    explanation: &gt;-
      Pectus deformity confirmed across all LDS types in clinical review.
- name: Joint Hypermobility
  description: &gt;
    Generalized joint hypermobility, contributing to joint dislocations
    and chronic pain. Extremity contractures in conjunction with joint
    hyperextension are unusual in the general population but common in LDS.
  phenotype_term:
    preferred_term: Joint hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Extremity contractures in conjunction with joint hyperextension are
      unusual in the general population but common in LDS
    explanation: &gt;-
      The coexistence of contractures and hypermobility is a distinctive
      feature of LDS.
- name: Cervical Spine Instability
  description: &gt;
    Cervical spine instability or malformation present in 51% of LDS 1/2
    patients. Requires assessment with flexion-extension X-rays.
  phenotype_term:
    preferred_term: Cervical spine instability
    term:
      id: HP:0010646
      label: Cervical spine instability
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Cervical spine findings are prominent features in LDS 1/2 (51%)
    explanation: &gt;-
      Over half of LDS type 1/2 patients have cervical spine abnormalities.
- name: Translucent Skin
  description: &gt;
    Thin, velvety, translucent skin with easy bruising and visible veins.
    Scars may be atrophic and wound healing delayed.
  phenotype_term:
    preferred_term: Translucent skin
    term:
      id: HP:0010648
      label: Dermal translucency
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Cutaneous findings in LDS include velvety, thin, translucent skin
      with easy bruising and visible veins
    explanation: &gt;-
      MacCarrick et al. describe the cutaneous features of LDS.
- name: Clubfoot
  description: &gt;
    Talipes equinovarus, present in a proportion of individuals.
  phenotype_term:
    preferred_term: Clubfoot
    term:
      id: HP:0001762
      label: Talipes equinovarus
- name: Osteoporosis
  description: &gt;
    Low bone mineral density and skeletal fragility, with at least 60%
    of patients having low or very low bone mineral density.
  phenotype_term:
    preferred_term: Osteoporosis
    term:
      id: HP:0000939
      label: Osteoporosis
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      at least 60% of patients had low or very low bone mineral density
      in the spine, hip, and/or femoral neck
    explanation: &gt;-
      High fracture risk and low BMD documented in LDS patients.
- name: Food Allergy
  description: &gt;
    High prevalence of food allergies (31% versus 6-8% in general
    population), with most common allergens being eggs, milk, soy,
    peanuts, and tree nuts.
  phenotype_term:
    preferred_term: Food allergy
    term:
      id: HP:0500093
      label: Food allergy
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      A conservative prevalence estimate of food allergies in this population
      is 31% (compared with 6-8% prevalence in the general population)
    explanation: &gt;-
      Food allergy prevalence is approximately 4-5 times higher in LDS
      than in the general population.
- name: Early-Onset Osteoarthritis
  description: &gt;
    Particularly prominent in LDS type 3 (SMAD3 mutations). Most affected
    individuals present with early-onset osteoarthritis with osteochondritis
    dissecans, onset as early as age 12.
  phenotype_term:
    preferred_term: Osteoarthritis
    term:
      id: HP:0002758
      label: Osteoarthritis
  evidence:
  - reference: PMID:21217753
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      In contrast with other aneurysm syndromes, most of these affected
      individuals presented with early-onset osteoarthritis
    explanation: &gt;-
      van de Laar et al. identified SMAD3 mutations as cause of
      aneurysms-osteoarthritis syndrome.
  - reference: PMID:35662564
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      LDS Type 3 demonstrated an increased prevalence of mitral valve
      prolapse and arthritis
    explanation: &gt;-
      Systematic review confirms LDS type 3 association with arthritis.
- name: Pregnancy-Related Vascular Complications
  description: &gt;
    High incidence of pregnancy-related complications including aortic
    dissection. Among 222 women with 522 pregnancies in a systematic review,
    4% experienced aortic dissection with 1% peripartum mortality.
  phenotype_term:
    preferred_term: Pregnancy complications
    term:
      id: HP:0001197
      label: Abnormality of prenatal development or birth
  evidence:
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      a high incidence of pregnancy-related complications (in 6 of 12 women)
    explanation: &gt;-
      50% pregnancy complication rate in initial LDS cohort.
  - reference: PMID:35662564
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Amongst 222 women who underwent 522 pregnancies, 4% experienced an
      aortic dissection and the peripartum mortality rate was 1%
    explanation: &gt;-
      Large systematic review quantifies pregnancy risks in LDS.
genetic:
- name: TGFBR1 Mutations (LDS Type 1)
  association: Causative
  notes: &gt;
    Heterozygous mutations in TGFBR1 encoding TGF-beta receptor type I.
    Most mutations cluster in the serine/threonine kinase domain. Accounts
    for 20-25% of LDS cases.
  variants:
  - name: Missense mutations in kinase domain
    description: &gt;
      Missense mutations in the intracellular kinase domain of TGFBR1
      that impair receptor signaling.
  evidence:
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      We found a mutation in TGFBR1 or TGFBR2 in all probands with typical
      Loeys-Dietz syndrome (type I) and in 12 probands presenting with
      vascular Ehlers-Danlos syndrome (Loeys-Dietz syndrome type II)
    explanation: &gt;-
      100% of typical LDS probands had TGFBR1 or TGFBR2 mutations.
- name: TGFBR2 Mutations (LDS Type 2)
  association: Causative
  notes: &gt;
    Heterozygous mutations in TGFBR2 encoding TGF-beta receptor type II.
    Mutations primarily affect the kinase domain. Most common genetic cause,
    accounting for 55-60% of LDS cases.
  variants:
  - name: Missense mutations in kinase domain
    description: &gt;
      Missense mutations affecting the kinase domain of TGFBR2.
  evidence:
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Mutations in either TGFBR1 or TGFBR2 predispose patients to
      aggressive and widespread vascular disease
    explanation: &gt;-
      Loeys et al. establish TGFBR2 mutations as causative for LDS.
- name: SMAD3 Mutations (LDS Type 3)
  association: Causative
  notes: &gt;
    Heterozygous mutations in SMAD3, an intracellular mediator of
    TGF-beta signaling. Associated with aneurysms-osteoarthritis syndrome.
  evidence:
  - reference: PMID:21217753
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      the disease is caused by mutations in SMAD3. This gene encodes
      a member of the TGF-beta pathway that is essential for TGF-beta
      signal transmission
    explanation: &gt;-
      van de Laar et al. identified SMAD3 as the causal gene for
      the aneurysms-osteoarthritis syndrome (LDS type 3).
- name: TGFB2 Mutations (LDS Type 4)
  association: Causative
  notes: &gt;
    Heterozygous mutations in TGFB2 encoding TGF-beta 2 ligand.
    Chromosome deletions encompassing TGFB2 causing haploinsufficiency
    are sufficient to cause LDS features.
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Chromosome deletions encompassing the TGFB2 gene (and hypothetically
      the SMAD3 gene) causing haploinsufficiency are sufficient to cause
      features of LDS
    explanation: &gt;-
      MacCarrick et al. describe TGFB2 haploinsufficiency as sufficient
      for LDS features.
- name: TGFB3 Mutations (LDS Type 5)
  association: Causative
  notes: &gt;
    Heterozygous mutations in TGFB3 encoding TGF-beta 3 ligand.
treatments:
- name: Prophylactic Aortic Root Replacement
  description: &gt;
    Valve-sparing aortic root replacement at lower thresholds than Marfan
    syndrome. For adults with LDS 1/2, surgical repair is recommended at
    4.0 cm maximal aortic root dimension. For children, aggressive medication
    may delay surgery until aortic annulus reaches 2.0-2.2 cm.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
    located_in:
      preferred_term: aorta
      term:
        id: UBERON:0000947
        label: aorta
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      For adults with LDS 1 or 2, this includes surgical repair of the
      aortic root once the maximal dimension of the aortic root reaches
      4.0 cm
    explanation: &gt;-
      MacCarrick et al. recommend surgical threshold of 4.0 cm for
      adult LDS patients, lower than the 5.0 cm for Marfan syndrome.
  - reference: PMID:16928994
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      There were 59 vascular surgeries in the cohort, with one death during
      the procedure. This low rate of intraoperative mortality distinguishes
      the Loeys-Dietz syndrome from vascular Ehlers-Danlos syndrome
    explanation: &gt;-
      Low surgical mortality supports aggressive prophylactic surgery
      approach in LDS, unlike vascular EDS.
- name: Losartan/ARB Therapy
  description: &gt;
    Angiotensin receptor blockers (particularly losartan) are used to
    reduce TGF-beta signaling. Losartan was shown to prevent aortic aneurysm
    in a mouse model by antagonizing TGF-beta through AT1 receptor blockade.
    Optimal dosing: 2.0 mg/kg/day for children, 100 mg/day for adults.
  evidence:
  - reference: PMID:16601194
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: &gt;-
      aortic aneurysm in a mouse model of MFS is associated with increased
      TGF-beta signaling and can be prevented by TGF-beta antagonists such
      as TGF-beta-neutralizing antibody or the angiotensin II type 1
      receptor (AT1) blocker, losartan
    explanation: &gt;-
      Habashi et al. provide the mechanistic rationale for losartan therapy
      in TGF-beta pathway disorders.
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Angiotensin receptor blockers may be particularly beneficial due to
      their effects on the TGF-beta signaling cascade
    explanation: &gt;-
      Clinical guidelines support ARB use for their pathway-specific effects
      beyond blood pressure reduction.
- name: Beta-Blocker Therapy
  description: &gt;
    Beta-blockers to reduce hemodynamic stress on the aorta. Standard-of-care
    for syndromic aneurysm conditions, often used in combination with ARBs.
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Beta-Blockade to reduce hemodynamic stress on the vasculature has been
      the standard-of-care treatment for individuals with syndromic aneurysm
      conditions
    explanation: &gt;-
      Beta-blockers are established standard of care for LDS vascular management.
- name: Comprehensive Vascular Surveillance
  description: &gt;
    Regular MRA or CTA imaging of the entire arterial tree from head to pelvis,
    as aneurysms can occur throughout the vascular system. Full vascular imaging
    at initial evaluation and at 2-year intervals if no aneurysms identified.
  evidence:
  - reference: PMID:24577266
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: &gt;-
      Diagnostic or baseline vascular imaging through magnetic resonance
      angiography or computerized tomography angiography with
      three-dimensional reconstruction of the head, neck, chest, abdomen,
      and pelvis should be performed
    explanation: &gt;-
      MacCarrick et al. recommend comprehensive head-to-pelvis imaging
      for all LDS patients.
datasets: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Loeys-Dietz_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>